BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is seeing exponential trading volume in stock and options after a 10% rise today.

Dynavax Technologies Corporation (NASDAQ: DVAX) is up over 50%after the FDA removed a clinical hold on its hepatitis treatment.

The fight over the Sepracor, Inc. (NASDAQ: SEPR) acquisition has now gone to the level of a class action status.  We noted the very low P/E and multiple valuations yesterday on this one.

StemCells, Inc. (NASDAQ: STEM) traded slightly higher on word that it will soon begin a study with the University of California, San Francisco Children’s Hospital using purified human neural stem cells as a possible treatment for Pelizaeus-Merzbacher Disease.

Pharmacyclics Inc. (NASDAQ: PCYC) was trading up on news that its right offering is oversubscribed.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) is trading higher on report that it has been assigned a Medicare HCPCS code for its recently introduced Microcyn Skin & Wound HydroGel.

JON C. OGG
SEPTEMBER 10, 2009

Abercrombie & Fitch (ANF) cut to Sell from Hold at Citi.
Fred’s Inc. (FRED) Cut to Market Perform at William Blair.
Family Dollar Stores (FDO) Cut to Market Perform at William Blair.

Finish Line (FINL) Started as Outperform at Wedbush Morgan.
Sepracor (SEPR) Raised to Neutral at Goldman Sachs.
Virgin Media (VMED) Started as Outperform by Credit Suisse.
Whitney Holding (WTNY) Raised to Buy at SunTrust Robinson Humphrey.
Zumiez (ZUMZ) Cut to Hold at KeyBanc.

JON C. OGG

Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) are bouncing by over 10% this morning now that equities have stopped the drop for now.

Hovnanian Enterprises Inc. (NYSE: HOV) is down about 10% … maybe all those ‘great home sales figures’ are either not so great or are not sustainable.

InnerWorkings Inc. (NASDAQ: INWK) is down sharply on an earnings warning.

Sun Microsystems Inc. (NASDAQ: JAVA) is down, but not as bad as you might think, on the EU probe of the Oracle Corp. (NASDAQ: ORCL) buyout…. Silly children must be in charge over there.

Sepracor, Inc. (NASDAQ: SEPR) is already at exponential trading volume on the buyout news.

Sinovac Biotech Ltd. (AMEX: SVA) is challenging $10.00 again… China approved it for a vaccine against swine flu for the Chinese market.

Zumiez Inc. (NASDAQ: ZUMZ) is up over 10% after negative same store sales were not as bad even at -12.1%… it caught 3 analyst upgrades.

You can join our open email distribution list which goes out several times per week if you wish to be notified by email when the top day trader alerts hit, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
SEPTEMBER 3, 2009

Rigel Pharmaceutical Inc. (Nasdaq: RIGL) shares are down sharply after its rheumatoid arthritis candidate missed its efficacy endpoint in a trial.

Microsoft Corp. (Nasdaq: MSFT) are the most active in the premarket, after it reported  lower-than-expected revenue that fell 17.3% from the same period last year.

SunPower Corp. (Nasdaq: SPWR) shares are among the biggest premarket gainers after the company posted a 10-cent a shre earnings beat, and gave upside guidance.

Align Technology Inc. (Nasdaq: ALGN) shares also are on the rise, after an earnings beat.

Amazon.com Inc. (Nasdaq: AMZN) shares are down nearly 6 percent as one of the most active decliners, after it reported in-line EPS.

Juniper Networks Inc. (Nasdaq: JNPR) shares are down on strong premarket volume despite better-than-expected earnings results, as gross margins were disappointing.

LM Ericsson Telephone Co. (Nasdaq: ERIC) shares are down 7 percent after it reported earnings this morning.

Sepracor Inc. (Nasdaq: SEPR) shares are up on strong volume following its earnings and raised fiscal 2009 guidance.

-The 24/7 Wall St. Team

Alnylam (ALNY) Started as Buy at Jefferies and at Roth.
Deutsche Bank (DB) Raised to Neutral at JPMorgan.
Drugstore.com (DDSCM) Started as Buy at Janney Montgomey Scott.
Olympic Steel (ZEUS) Raised to Buy at KeyBanc.
Sepracor (SEPR) Started as Buy at Sun Trust Robinson Humphrey.
US Steel (X) Raised to Buy at KeyBanc.
Yahoo! (YHOO) Raised to Buy at Soleil.

JON C. OGG

Adobe Systems (ADBE) Cut to Hold at Citigroup; Cut to Neutral at UBS.
Bankrate (RATE) Cut to Market Perform at JMP Securities.
BorgWarner Inc. (BWA) Cut to Equal Weight at Barclays.
Marathon Oil (MRO) Cut to Neutral at Credit Suisse.
Red Hat (RHT) Raised to Buy at UBS.
Sepracor (SEPR) Raised to Overweight at JPMorgan.
Symantec (SYMC) Raised to Overweight at Thomas Weisel.
Sina Corp. (SINA) Cut to Perform at Oppenheimer.

JON C. OGG

• Alcatel-Lucent (NYSE: ALU) Cut to Underperform at Jefferies.
• AU Optronics (NYSE: AUO) Cut to Neutral at Credit Suisse.
• Beckman Coulter (NYSE: BEC) Cut to Neutral at Baird.
• Boeing (NYSE: BA) Started as Sell at Societe Generale.
• Goodrich (NYSE: GR) Started as Sell at Society Generale.
• Kansas City Southern (NYSE: KSU) Cut to Neutral at Goldman Sachs.
• Lululemon Athletica (NASDAQ: LULU) Cut to Perform at Oppenheimer.
• Sepracor (NASDAQ: SEPR) Started as Sell at Goldman Sachs.

Jon C. Ogg
December 15, 2008

Institutions have been selling the stock today from $24.30 to $24.50 rather than waiting for the $25.00 and this had traded more than 180 million shares late in the day (more than $4.3 Billion worth of stock).  As the institutions take this money out, that theoretically ends up in other similar criteria companies.  Of course this is only a very partial list, and we wouldn’t want to believe that those funds will only go into ‘identical criteria" emerging pharma and biotech stocks in the U.S. alone.  But here is a partial list of stocks that have somewhat similar characteristics that could be some of the beneficiaries in this scenario:

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) with a $2.5 Billion market cap is now in its second transitionary year where revenues went from partnership and interest revenues into product revenues as analysts expect more than $213 million in 2008 revenues and more than $360 million for 2009.  Currently markets Soliris for blood disorders.

Cephalon, Inc. (NASDAQ: CEPH) has a $4.4 Billion market cap and established revenues of $1.77 Billion last year.  Analysts expect revenues to be $1.88 Billion this year and more than $2.1 Billion next year.  It already has drugs in place or in development for central nervous system disorders, pain, oncology, and addiction.

Cubist Pharmaceuticals Inc. (NASDAQ: CBST) may be a tad small with a $1.1 Billion market cap and with fresh contamination problems, but its name wasn’t left off.  2007 saw $294+ million in revenues, and analysts are looking for revenues of $391 million this year and $479 million next year.  Company’s Cubicin is on market as the first antibiotic in a new class of anti-infectives called lipopeptides for strep, staph, and other infections.

Imclone Systems (NASDAQ: IMCL) would have matched with a $3.8 Billion market cap and Erbitux as a current cancer drug, although this has been between $30 and $45.00 per share since its huge drop in 2004 and activists haven’t been able to make it budge.

Onyx Pharmaceuticals Inc. (ONXX) has a $1.9 Billion market cap and it has also transitioned to a revenue generator with analysts expecting revenues of $80 million this year and $161 million next year.  Nexavar is its kidney cancer and tumor drug, plus other partner studies in place.

Sepracor Inc. (NASDAQ: SEPR) has a $2.4 Billion market cap and is also in the revenue generation stage, although it has been a painful stock for many investors over the last 12 to 18 months.  Revenues are already established and analysts expect revenues to be $1.35 Billion this year and $1.53 Billion next year.  LUNESTA is major product, has key partners in place. 

United Therapeutics Corp. (NASDAQ: UTHR) has a market cap of $1.9 Billion and generated almost $211 million in 2007 revenues.  Analysts expect revenues to hit $261+ million this year and $346+ million next year.  Drugs treat cardiovascular, cancer, and infectious diseases.

You can join our open email distribution list to hear about special financings, secondary offerings, IPO’s, M&A, and more previews for other special situations in various stages.

Jon C. Ogg
April 10, 2008

Jon Ogg produces the Special Situation Investing Newsletter.  He can be reached at jonogg@247wallst.com and he does not own securities in the companies he covers.

• Air Tran (NYSE: AAI) -$0.02 EPS vs -$0.02 estimate.
• American Electric Power (NYSE: AEP) $0.52 EPS vs $0.50 estimate.
• American Express (NYSE: AXP) $0.71 EPS vs $0.71 estimate; stock fell 2% after-hours.
• Burlington Northern (NYSE: BNI) $1.46 EPS vs $1.37 estimate.
• Cardinal Health (NYSE: CAH) $0.90 EPS vs. $0.87 estimate, lowered guidance.
• Chattem (NASDAQ: CHTT) $0.76 EPS vs $0.65 estimate.
• Corinthian Colleges (NASDAQ: COCO) $0.11 EPS vs. $0.11 estimate; lending changes and reimbursement changes will lower earnings in second half to make 2008 at lower-end of expectations.
• Countrywide Financial (NYSE: CFC) posted earnings; maintained dividend; shares up 1.5% pre-market.
• Dow Chemical (NYSE: DOW) $0.84 EPS vs $0.80 estimate;
• Eli Lilly (NYSE: LLY) $0.90 EPS vs $0.87 estimate.
• EMC (NYSE: EMC) $0.24 EPS vs $0.22 estimate
• 3M (NYSE: MMM) $1.19 EPS vs $1.17 estimate; $6.2 Billion vs. $6.12B estimate; reiterated 10% EPS growth for 2008.
• Accidental Petroleum (NYSE: OXY) $1.74 EPS vs $1.69 estimate; replaced 116% of its 2007 production.
• SanDisk (NASDAQ: SNDK) posted non-GAAP EPS of $0.69 vs. $0.64 EPS estimate, but guidance was disappointing; stock down 3%.
• Sepracor (NASDAQ: SEPR) trading down 7% after restatements.
• Smurfit Stone (NASDAQ: SSCC) traded up 6% after earnings.
• T.Rowe Price (NASDAQ: TROW) $0.68 EPS vs $0.63 estimate.
• Unisys (NYSE: UIS) $0.04 EPS vs $0.12 estimate; although shares up almost 4%.
• VMware (NYSE: VMW) trading down 20% or more after revenue number was light.
• Waddell & Reed (NYSE: WDR) $0.42 EPS vs. $0.42 estimate.
• Zoran (NASDAQ: ZRAN) traded down 22% after beating earnings but lowering guidance.

Jon C. Ogg
January 29, 2008